Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire/Baxalta Merger's Benefits Doubted By Wall Street

This article was originally published in Scrip

Executive Summary

The successful culmination of Shire PLC's months-long pursuit of Baxalta Inc. to create the world's biggest rare disease company generally was seen as a good thing by analysts, but they question how much value acquiring the Baxter International Inc. spinout for approximately $32bn truly will bring to the Irish specialty pharma. Concerns center on the long-term viability of Baxalta's hemophilia franchise and whether the total benefits warrant the price being paid.

You may also be interested in...



Shire May Split Up – But Punting On Bigger Decisions For Now

The specialty pharma is dividing its operations into rare disease and neuroscience units, but whether that will mean a spinout for the latter won't be revealed for months.

Shire Outlines Baxalta Integration Strategy

First quarter financial results brought another growth period for Shire PLC, but perhaps the most noteworthy information provided by the company on its April 29 earnings call, was its strategy for integrating Baxalta Inc. into its infrastructure, assuming both companies' boards approve the transaction when they meet separately on May 27.

Mitsubishi’s Oral Radicava Provides Convenience Option For ALS

Oral or feeding tube administration of the cerebral neuroprotectant should offer flexible dosing options for amyotrophic lateral sclerosis patients, the firm says.

Topics

UsernamePublicRestriction

Register

SC064189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel